Antibody-drug Conjugate/ADC Related

Biotechno Labs have partnered with Medchem Express to fulfill the needs of antibody-drug conjugates by the scientific community. MedChemExpress (MCE) offers a wide range of high-quality research chemicals and The scientific team at MedChemExpress (MCE) is highly experienced and has a successful track record in molecular synthesis. They are proficient in the synthesis of milligram to kilogram scale of structurally diverse and synthetically challenging molecules.

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug.